Selpercatinib Extends PFS in First-line RET-Positive NSCLC

A randomized trial found that selpercatinib improved PFS by more than two-fold, but overall survival data remain immature.

Related Keywords

,Eli Lilly ,Fung Loong ,European Society For Medical Oncology ,Chinese University Of Hong Kong ,Herbert Ho Fung Loong ,Chinese University ,Hong Kong ,Medical Oncology ,New England Journal ,Non Small Cell Lung Cancer ,Nsclc ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Brain Metastasis ,Metastatic Brain Tumor ,Metastasis ,Malignant Head And Neck Neoplasm ,Brain ,Malignant Secondary Lung Neoplasm ,Etastasis Lung ,Hepatocellular Carcinoma ,Liver Cancer ,Dcc ,Hepatocellular Cancer ,Ancer Liver ,Ancer Hepatocellular ,Aminotransferase ,Dust ,Liver Enzymes ,Liver Studies ,Olt ,Genomics ,Reno ,